{"id":"88672326-81b7-4b7d-b09d-0517fbf4aee7","url":"https://clinicalintelpulse.theaslangroupllc.com/api/clinical/trial-brief?lang=en+%7C+es+%7C+fr+%7C+de+%7C+ja+%7C+zh+%7C+ko+%7C+pt+%7C+ar+%7C+hi+%28default%3A+en%29&nct_id=NCT+identifier+%E2%80%94+e.g.+%22NCT04368728%22+%7C+%22NCT05116748%22+%7C+%22NCT04815993%22","method":"GET","fingerprint":"2e32e406e353ac1be03696611c344c7cdb98d576d4ed2ba86faf08d62a585c66","name":"ClinicalIntelPulse","description":null,"category":"other","docs_url":null,"advertised_price_usd":"0.100000","asset":"0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913","scheme":"exact","networks":["eip155:8453","solana:5eykt4UsFv8P8NJdTREpY1vzqKqZKvdp","eip155:137","eip155:42161","eip155:480","eip155:143","eip155:196","eip155:999","algorand:wGHE2Pwdvd7S12BL5FaOP20EGYesN73k","xrpl:0","eip155:56"],"pay_to":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","input_schema":{"type":"object","required":["type","method"],"properties":{"type":{"type":"string","const":"http"},"method":{"enum":["GET","HEAD","DELETE"],"type":"string"},"queryParams":{"type":"object","properties":{"lang":{"type":"string"},"nct_id":{"type":"string"}}}},"additionalProperties":false},"output_schema":{"type":"object","required":["type"],"properties":{"type":{"type":"string"},"errors":{"type":"object","description":"Documented error responses, keyed by HTTP status code","additionalProperties":{"type":"object","required":["description"],"properties":{"example":{"type":"object"},"description":{"type":"string"}}}},"example":{"type":"object"}}},"schema_completeness":0,"status":"live","first_seen_at":"2026-08-23 12:34:34.822373+00","last_seen_at":"2026-08-23 16:41:23.534+00","last_success_at":"2026-10-15 11:47:00.851+00","dead_since":null,"probe_backoff_tier":0,"next_probe_at":"2026-10-15 11:52:00.851+00","search_tsv":"'clinicalintelpuls':1","catalog_number":"5242","x402_version":2,"resource_url":"https://clinicalintelpulse.theaslangroupllc.com/api/clinical/trial-brief","resource_description":"Clinical trial deep dive by NCT ID — full trial design, primary/secondary endpoints, enrollment status and countries, sponsor, recruitment criteria, outcomes and publications for any ClinicalTrials.gov study. For research and biotech agents.","bazaar_extension":{"info":{"input":{"type":"http","method":"GET","queryParams":{"lang":"en | es | fr | de | ja | zh | ko | pt | ar | hi (default: en)","nct_id":"NCT identifier — e.g. \"NCT04368728\" | \"NCT05116748\" | \"NCT04815993\""}},"output":{"type":"json","errors":{"400":{"example":{"error":"invalid request"},"description":"Invalid or missing parameter(s). Returned before the payment gate on paid requests, so a malformed call is never charged. JSON body: { error: <what is wrong and how to fix it> } plus usage hints."},"402":{"description":"Payment required — x402 v2 challenge; the accepts array lists scheme, network, and amount. Retry the same request with a PAYMENT-SIGNATURE (v2) or X-PAYMENT (v1) header. Verification is free."},"500":{"example":{"error":"upstream_failed"},"description":"Unexpected server error. If a payment settled without a usable result, contact info@theaslangroupllc.com with the settlement tx hash for a re-run or credit."}},"example":{"design":{"arms":["Tiragolumab + Atezolizumab + Carboplatin/Paclitaxel","Placebo + Atezolizumab + Carboplatin/Paclitaxel"],"masking":"Double-Blind","allocation":"Randomized","study_type":"INTERVENTIONAL","primary_purpose":"Treatment"},"endpoints":{"primary":["Progression-Free Survival (PFS)","Overall Survival (OS)"],"secondary":["Objective Response Rate","Duration of Response","Safety/Tolerability"]},"enrollment":{"actual":534,"planned":534,"countries":["United States","Spain","Germany","Japan","Australia"]},"interventions":[{"name":"Tiragolumab","role":"Anti-TIGIT immune checkpoint inhibitor","type":"DRUG"}],"query_summary":{"nct_id":"NCT04368728","retrieved_from":"ClinicalTrials.gov v2 API"},"trial_identity":{"phase":"PHASE3","title":"A Study of Tiragolumab in Combination With Atezolizumab and Chemotherapy Versus Placebo in Untreated Locally Advanced Unresectable or Metastatic NSCLC (SKYSCRAPER-01)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","start_date":"2019-06","primary_completion":"2022-12"},"outcome_summary":"SKYSCRAPER-01 failed to meet primary PFS endpoint (HR 0.93). Significant negative readout for anti-TIGIT in NSCLC.","regulatory_implications":"Setback for Roche tiragolumab program. Broader TIGIT class facing headwinds."}}},"schema":{"type":"object","$schema":"https://json-schema.org/draft/2020-12/schema","required":["input"],"properties":{"input":{"type":"object","required":["type","method"],"properties":{"type":{"type":"string","const":"http"},"method":{"enum":["GET","HEAD","DELETE"],"type":"string"},"queryParams":{"type":"object","properties":{"lang":{"type":"string"},"nct_id":{"type":"string"}}}},"additionalProperties":false},"output":{"type":"object","required":["type"],"properties":{"type":{"type":"string"},"errors":{"type":"object","description":"Documented error responses, keyed by HTTP status code","additionalProperties":{"type":"object","required":["description"],"properties":{"example":{"type":"object"},"description":{"type":"string"}}}},"example":{"type":"object"}}}}}},"accepted_requirements":[{"raw":{"asset":"0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913","extra":{"name":"USD Coin","version":"2"},"payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","amount":"100000","scheme":"exact","network":"eip155:8453","maxTimeoutSeconds":300},"asset":"0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913","payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","scheme":"exact","network":"eip155:8453","amountAtomic":"100000"},{"raw":{"asset":"0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913","extra":{"name":"GatewayWalletBatched","version":"1","verifyingContract":"0x77777777dcc4d5a8b6e418fd04d8997ef11000ee"},"payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","amount":"100000","scheme":"exact","network":"eip155:8453","maxTimeoutSeconds":604900},"asset":"0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913","payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","scheme":"exact","network":"eip155:8453","amountAtomic":"100000"},{"raw":{"asset":"EPjFWdd5AufqSSqeM2qN1xzybapC8G4wEGGkZwyTDt1v","extra":{"feePayer":"GVJJ7rdGiXr5xaYbRwRbjfaJL7fmwRygFi1H6aGqDveb"},"payTo":"985iFjbnGQ3dJcwXnfRCMSrH4Jnc3kW1N6msR64B5KX1","amount":"100000","scheme":"exact","network":"solana:5eykt4UsFv8P8NJdTREpY1vzqKqZKvdp","maxTimeoutSeconds":300},"asset":"EPjFWdd5AufqSSqeM2qN1xzybapC8G4wEGGkZwyTDt1v","payTo":"985iFjbnGQ3dJcwXnfRCMSrH4Jnc3kW1N6msR64B5KX1","scheme":"exact","network":"solana:5eykt4UsFv8P8NJdTREpY1vzqKqZKvdp","amountAtomic":"100000"},{"raw":{"asset":"0x3c499c542cEF5E3811e1192ce70d8cC03d5c3359","extra":{"name":"USD Coin","version":"2"},"payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","amount":"100000","scheme":"exact","network":"eip155:137","maxTimeoutSeconds":300},"asset":"0x3c499c542cEF5E3811e1192ce70d8cC03d5c3359","payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","scheme":"exact","network":"eip155:137","amountAtomic":"100000"},{"raw":{"asset":"0xaf88d065e77c8cC2239327C5EDb3A432268e5831","extra":{"name":"USD Coin","version":"2"},"payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","amount":"100000","scheme":"exact","network":"eip155:42161","maxTimeoutSeconds":300},"asset":"0xaf88d065e77c8cC2239327C5EDb3A432268e5831","payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","scheme":"exact","network":"eip155:42161","amountAtomic":"100000"},{"raw":{"asset":"0x79A02482A880bCe3F13E09da970dC34dB4cD24D1","extra":{"name":"USDC","version":"2"},"payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","amount":"100000","scheme":"exact","network":"eip155:480","maxTimeoutSeconds":300},"asset":"0x79A02482A880bCe3F13E09da970dC34dB4cD24D1","payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","scheme":"exact","network":"eip155:480","amountAtomic":"100000"},{"raw":{"asset":"0x754704Bc059F8C67012fEd69BC8A327a5aafb603","extra":{"name":"USDC","version":"2"},"payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","amount":"100000","scheme":"exact","network":"eip155:143","maxTimeoutSeconds":300},"asset":"0x754704Bc059F8C67012fEd69BC8A327a5aafb603","payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","scheme":"exact","network":"eip155:143","amountAtomic":"100000"},{"raw":{"asset":"0x779ded0c9e1022225f8e0630b35a9b54be713736","extra":{"name":"USD₮0","version":"1"},"payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","amount":"100000","scheme":"exact","network":"eip155:196","maxTimeoutSeconds":300},"asset":"0x779ded0c9e1022225f8e0630b35a9b54be713736","payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","scheme":"exact","network":"eip155:196","amountAtomic":"100000"},{"raw":{"asset":"0xb88339CB7199b77E23DB6E890353E22632Ba630f","extra":{"name":"USDC","version":"2"},"payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","amount":"100000","scheme":"exact","network":"eip155:999","maxTimeoutSeconds":300},"asset":"0xb88339CB7199b77E23DB6E890353E22632Ba630f","payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","scheme":"exact","network":"eip155:999","amountAtomic":"100000"},{"raw":{"asset":"31566704","extra":{"feePayer":"ZMFK2OI7ZBD2U27ISERZC4S6LKM6WMFJPZQ4MYNJDZ2VNBNMBA67RA22AA"},"payTo":"62A253YPATFNJCPRKID3FKD77MYJFNTVRYRP4B4JWG36EGLPY7UXFWGI7I","amount":"100000","scheme":"exact","network":"algorand:wGHE2Pwdvd7S12BL5FaOP20EGYesN73k","maxTimeoutSeconds":300},"asset":"31566704","payTo":"62A253YPATFNJCPRKID3FKD77MYJFNTVRYRP4B4JWG36EGLPY7UXFWGI7I","scheme":"exact","network":"algorand:wGHE2Pwdvd7S12BL5FaOP20EGYesN73k","amountAtomic":"100000"},{"raw":{"asset":"XRP","extra":{"invoiceId":"BACB2786983E4A7B9829D70422913D80","sourceTag":804681468},"payTo":"rMnHeutYALco8RYFVcmuU4BCgSzBpPEh32","amount":"100000","scheme":"exact","network":"xrpl:0","maxTimeoutSeconds":300},"asset":"XRP","payTo":"rMnHeutYALco8RYFVcmuU4BCgSzBpPEh32","scheme":"exact","network":"xrpl:0","amountAtomic":"100000"},{"raw":{"asset":"524C555344000000000000000000000000000000","extra":{"issuer":"rMxCKbEDwqr76QuheSUMdEGf4B9xJ8m5De","invoiceId":"706EEF81C05E48F1A980CF09CF157E4C","sourceTag":804681468},"payTo":"rMnHeutYALco8RYFVcmuU4BCgSzBpPEh32","amount":"0.1","scheme":"exact","network":"xrpl:0","maxTimeoutSeconds":300},"asset":"524C555344000000000000000000000000000000","payTo":"rMnHeutYALco8RYFVcmuU4BCgSzBpPEh32","scheme":"exact","network":"xrpl:0","amountAtomic":"0.1"},{"raw":{"asset":"0x8d0D000Ee44948FC98c9B98A4FA4921476f08B0d","extra":{"name":"World Liberty Financial USD","version":"1","signerAddress":"0x34F7a661160780Ce1346e6D7B96D2bE244590899","assetTransferMethod":"eip3009"},"payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","amount":"100000000000000000","scheme":"exact","network":"eip155:56","maxTimeoutSeconds":300},"asset":"0x8d0D000Ee44948FC98c9B98A4FA4921476f08B0d","payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","scheme":"exact","network":"eip155:56","amountAtomic":"100000000000000000"}],"bazaar_compatible":true,"bazaar_validated_at":"2026-10-15 11:47:00.851+00","bazaar_validation_error":null,"window":"24h","probes_n":10,"handshake_uptime":1,"settle_success_rate":0,"valid_result_rate":null,"latency_p50":462,"latency_p90":1020,"price_drift_pct":0,"score":0.8341,"computed_at":"2026-10-15 11:47:09.123+00","source_metadata":[{"raw":{"url":"https://clinicalintelpulse.theaslangroupllc.com/api/clinical/trial-brief?lang=en+%7C+es+%7C+fr+%7C+de+%7C+ja+%7C+zh+%7C+ko+%7C+pt+%7C+ar+%7C+hi+%28default%3A+en%29&nct_id=NCT+identifier+%E2%80%94+e.g.+%22NCT04368728%22+%7C+%22NCT05116748%22+%7C+%22NCT04815993%22","name":"ClinicalIntelPulse","method":"GET","source":"bazaar:api.cdp.coinbase.com","fingerprint":"2e32e406e353ac1be03696611c344c7cdb98d576d4ed2ba86faf08d62a585c66","advertisedPriceUsd":0.1},"source_id":1,"external_id":null}],"live_endpoint_metadata":{"x402_version":2,"resource_url":"https://clinicalintelpulse.theaslangroupllc.com/api/clinical/trial-brief","resource_description":"Clinical trial deep dive by NCT ID — full trial design, primary/secondary endpoints, enrollment status and countries, sponsor, recruitment criteria, outcomes and publications for any ClinicalTrials.gov study. For research and biotech agents.","bazaar_extension":{"info":{"input":{"type":"http","method":"GET","queryParams":{"lang":"en | es | fr | de | ja | zh | ko | pt | ar | hi (default: en)","nct_id":"NCT identifier — e.g. \"NCT04368728\" | \"NCT05116748\" | \"NCT04815993\""}},"output":{"type":"json","errors":{"400":{"example":{"error":"invalid request"},"description":"Invalid or missing parameter(s). Returned before the payment gate on paid requests, so a malformed call is never charged. JSON body: { error: <what is wrong and how to fix it> } plus usage hints."},"402":{"description":"Payment required — x402 v2 challenge; the accepts array lists scheme, network, and amount. Retry the same request with a PAYMENT-SIGNATURE (v2) or X-PAYMENT (v1) header. Verification is free."},"500":{"example":{"error":"upstream_failed"},"description":"Unexpected server error. If a payment settled without a usable result, contact info@theaslangroupllc.com with the settlement tx hash for a re-run or credit."}},"example":{"design":{"arms":["Tiragolumab + Atezolizumab + Carboplatin/Paclitaxel","Placebo + Atezolizumab + Carboplatin/Paclitaxel"],"masking":"Double-Blind","allocation":"Randomized","study_type":"INTERVENTIONAL","primary_purpose":"Treatment"},"endpoints":{"primary":["Progression-Free Survival (PFS)","Overall Survival (OS)"],"secondary":["Objective Response Rate","Duration of Response","Safety/Tolerability"]},"enrollment":{"actual":534,"planned":534,"countries":["United States","Spain","Germany","Japan","Australia"]},"interventions":[{"name":"Tiragolumab","role":"Anti-TIGIT immune checkpoint inhibitor","type":"DRUG"}],"query_summary":{"nct_id":"NCT04368728","retrieved_from":"ClinicalTrials.gov v2 API"},"trial_identity":{"phase":"PHASE3","title":"A Study of Tiragolumab in Combination With Atezolizumab and Chemotherapy Versus Placebo in Untreated Locally Advanced Unresectable or Metastatic NSCLC (SKYSCRAPER-01)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","start_date":"2019-06","primary_completion":"2022-12"},"outcome_summary":"SKYSCRAPER-01 failed to meet primary PFS endpoint (HR 0.93). Significant negative readout for anti-TIGIT in NSCLC.","regulatory_implications":"Setback for Roche tiragolumab program. Broader TIGIT class facing headwinds."}}},"schema":{"type":"object","$schema":"https://json-schema.org/draft/2020-12/schema","required":["input"],"properties":{"input":{"type":"object","required":["type","method"],"properties":{"type":{"type":"string","const":"http"},"method":{"enum":["GET","HEAD","DELETE"],"type":"string"},"queryParams":{"type":"object","properties":{"lang":{"type":"string"},"nct_id":{"type":"string"}}}},"additionalProperties":false},"output":{"type":"object","required":["type"],"properties":{"type":{"type":"string"},"errors":{"type":"object","description":"Documented error responses, keyed by HTTP status code","additionalProperties":{"type":"object","required":["description"],"properties":{"example":{"type":"object"},"description":{"type":"string"}}}},"example":{"type":"object"}}}}}},"accepted_requirements":[{"raw":{"asset":"0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913","extra":{"name":"USD Coin","version":"2"},"payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","amount":"100000","scheme":"exact","network":"eip155:8453","maxTimeoutSeconds":300},"asset":"0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913","payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","scheme":"exact","network":"eip155:8453","amountAtomic":"100000"},{"raw":{"asset":"0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913","extra":{"name":"GatewayWalletBatched","version":"1","verifyingContract":"0x77777777dcc4d5a8b6e418fd04d8997ef11000ee"},"payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","amount":"100000","scheme":"exact","network":"eip155:8453","maxTimeoutSeconds":604900},"asset":"0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913","payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","scheme":"exact","network":"eip155:8453","amountAtomic":"100000"},{"raw":{"asset":"EPjFWdd5AufqSSqeM2qN1xzybapC8G4wEGGkZwyTDt1v","extra":{"feePayer":"GVJJ7rdGiXr5xaYbRwRbjfaJL7fmwRygFi1H6aGqDveb"},"payTo":"985iFjbnGQ3dJcwXnfRCMSrH4Jnc3kW1N6msR64B5KX1","amount":"100000","scheme":"exact","network":"solana:5eykt4UsFv8P8NJdTREpY1vzqKqZKvdp","maxTimeoutSeconds":300},"asset":"EPjFWdd5AufqSSqeM2qN1xzybapC8G4wEGGkZwyTDt1v","payTo":"985iFjbnGQ3dJcwXnfRCMSrH4Jnc3kW1N6msR64B5KX1","scheme":"exact","network":"solana:5eykt4UsFv8P8NJdTREpY1vzqKqZKvdp","amountAtomic":"100000"},{"raw":{"asset":"0x3c499c542cEF5E3811e1192ce70d8cC03d5c3359","extra":{"name":"USD Coin","version":"2"},"payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","amount":"100000","scheme":"exact","network":"eip155:137","maxTimeoutSeconds":300},"asset":"0x3c499c542cEF5E3811e1192ce70d8cC03d5c3359","payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","scheme":"exact","network":"eip155:137","amountAtomic":"100000"},{"raw":{"asset":"0xaf88d065e77c8cC2239327C5EDb3A432268e5831","extra":{"name":"USD Coin","version":"2"},"payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","amount":"100000","scheme":"exact","network":"eip155:42161","maxTimeoutSeconds":300},"asset":"0xaf88d065e77c8cC2239327C5EDb3A432268e5831","payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","scheme":"exact","network":"eip155:42161","amountAtomic":"100000"},{"raw":{"asset":"0x79A02482A880bCe3F13E09da970dC34dB4cD24D1","extra":{"name":"USDC","version":"2"},"payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","amount":"100000","scheme":"exact","network":"eip155:480","maxTimeoutSeconds":300},"asset":"0x79A02482A880bCe3F13E09da970dC34dB4cD24D1","payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","scheme":"exact","network":"eip155:480","amountAtomic":"100000"},{"raw":{"asset":"0x754704Bc059F8C67012fEd69BC8A327a5aafb603","extra":{"name":"USDC","version":"2"},"payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","amount":"100000","scheme":"exact","network":"eip155:143","maxTimeoutSeconds":300},"asset":"0x754704Bc059F8C67012fEd69BC8A327a5aafb603","payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","scheme":"exact","network":"eip155:143","amountAtomic":"100000"},{"raw":{"asset":"0x779ded0c9e1022225f8e0630b35a9b54be713736","extra":{"name":"USD₮0","version":"1"},"payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","amount":"100000","scheme":"exact","network":"eip155:196","maxTimeoutSeconds":300},"asset":"0x779ded0c9e1022225f8e0630b35a9b54be713736","payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","scheme":"exact","network":"eip155:196","amountAtomic":"100000"},{"raw":{"asset":"0xb88339CB7199b77E23DB6E890353E22632Ba630f","extra":{"name":"USDC","version":"2"},"payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","amount":"100000","scheme":"exact","network":"eip155:999","maxTimeoutSeconds":300},"asset":"0xb88339CB7199b77E23DB6E890353E22632Ba630f","payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","scheme":"exact","network":"eip155:999","amountAtomic":"100000"},{"raw":{"asset":"31566704","extra":{"feePayer":"ZMFK2OI7ZBD2U27ISERZC4S6LKM6WMFJPZQ4MYNJDZ2VNBNMBA67RA22AA"},"payTo":"62A253YPATFNJCPRKID3FKD77MYJFNTVRYRP4B4JWG36EGLPY7UXFWGI7I","amount":"100000","scheme":"exact","network":"algorand:wGHE2Pwdvd7S12BL5FaOP20EGYesN73k","maxTimeoutSeconds":300},"asset":"31566704","payTo":"62A253YPATFNJCPRKID3FKD77MYJFNTVRYRP4B4JWG36EGLPY7UXFWGI7I","scheme":"exact","network":"algorand:wGHE2Pwdvd7S12BL5FaOP20EGYesN73k","amountAtomic":"100000"},{"raw":{"asset":"XRP","extra":{"invoiceId":"BACB2786983E4A7B9829D70422913D80","sourceTag":804681468},"payTo":"rMnHeutYALco8RYFVcmuU4BCgSzBpPEh32","amount":"100000","scheme":"exact","network":"xrpl:0","maxTimeoutSeconds":300},"asset":"XRP","payTo":"rMnHeutYALco8RYFVcmuU4BCgSzBpPEh32","scheme":"exact","network":"xrpl:0","amountAtomic":"100000"},{"raw":{"asset":"524C555344000000000000000000000000000000","extra":{"issuer":"rMxCKbEDwqr76QuheSUMdEGf4B9xJ8m5De","invoiceId":"706EEF81C05E48F1A980CF09CF157E4C","sourceTag":804681468},"payTo":"rMnHeutYALco8RYFVcmuU4BCgSzBpPEh32","amount":"0.1","scheme":"exact","network":"xrpl:0","maxTimeoutSeconds":300},"asset":"524C555344000000000000000000000000000000","payTo":"rMnHeutYALco8RYFVcmuU4BCgSzBpPEh32","scheme":"exact","network":"xrpl:0","amountAtomic":"0.1"},{"raw":{"asset":"0x8d0D000Ee44948FC98c9B98A4FA4921476f08B0d","extra":{"name":"World Liberty Financial USD","version":"1","signerAddress":"0x34F7a661160780Ce1346e6D7B96D2bE244590899","assetTransferMethod":"eip3009"},"payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","amount":"100000000000000000","scheme":"exact","network":"eip155:56","maxTimeoutSeconds":300},"asset":"0x8d0D000Ee44948FC98c9B98A4FA4921476f08B0d","payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","scheme":"exact","network":"eip155:56","amountAtomic":"100000000000000000"}],"bazaar_compatible":true,"bazaar_validated_at":"2026-10-15 11:47:00.851+00","bazaar_validation_error":null},"sonar_metrics":{"score":0.8341,"uptime":1,"paid_success_rate":0,"valid_result_rate":null,"latency_p50":462,"latency_p90":1020,"price_drift_pct":0},"cdp_indexed":false,"confidence":"medium"}